6th Edition of International Conference on Tissue Engineering and Regenerative Medicine
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 6th Edition of International Conference on Tissue Engineering and Regenerative Medicine — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
6th Edition of International Conference on Tissue Engineering and Regenerative Medicine
Dates: November 18–20, 2026 | Venue: Berlin, Germany
The 6th Edition of the International Conference on Tissue Engineering and Regenerative Medicine (ICTERM 2026) brings together leading scientists, researchers, clinicians, and industry pioneers to advance innovations in tissue regeneration, stem cell therapies, and bioengineering. This interdisciplinary event serves as a global platform to discuss cutting-edge research, translational applications, and future directions in regenerative medicine, fostering collaborations across academia, healthcare, and biotechnology sectors.
Conference Overview
ICTERM 2026 will explore breakthroughs in tissue engineering, biomaterials, 3D biofabrication, and cell-based therapies. The program includes keynote speeches, panel discussions, poster presentations, and networking sessions designed to bridge gaps between theoretical research and clinical implementation.
Key Highlights
- Interdisciplinary approach to tissue regeneration and regenerative therapies
- Focus on translational research and commercialization of regenerative solutions
- Exhibition of advanced technologies in biofabrication, stem cell isolation, and bioreactors
- Workshops on ethical considerations, regulatory frameworks, and funding opportunities
Target Audience
- Academic researchers in biomedical engineering and life sciences
- Clinicians specializing in orthopedics, cardiology, dermatology, and neurology
- Biotech and pharmaceutical industry professionals
- Policy-makers and regulatory affairs experts
- Students and early-career scientists
Conference Objectives
To facilitate global dialogue on challenges and opportunities in tissue engineering, promote interdisciplinary collaboration, and accelerate the development of regenerative therapies for clinical applications. The conference also aims to educate emerging researchers and foster partnerships between academia and industry.
Key Focus Areas
- 3D Bioprinting and Organoid Development
- Stem Cell Therapies and Immunomodulation
- Biomaterials and Scaffolding Design
- Wound Healing and Skin Regeneration
- Cardiovascular and Neural Tissue Engineering
- Ethical and Regulatory Challenges in Regenerative Medicine
Why Attend?
ICTERM 2026 offers unparalleled opportunities to engage with global experts, explore innovative technologies, and stay updated on the latest advancements in the field. Participants will gain insights into emerging trends, funding mechanisms, and potential collaborations to drive their research and business objectives.
Call for Participation
Researchers, clinicians, and industry leaders are invited to submit abstracts for oral or poster presentations. Early registration is recommended to secure discounted rates and accommodations. For more details, visit ICTERM 2026 Official Website.
Data sheet
6th Edition of International Conference on Tissue Engineering and Regenerative Medicine – Event Attendee & Buyer Profile Analysis
Event date: 28 September 2026 – 30 September 2026
Location: Delta Hotels Heathrow Windsor, Ditton Rd, Langley, Slough SL3 8PT, United Kingdom
Event status: Upcoming
Research date: 30 June 2026
Event Overview
| Event Name | 6th Edition of International Conference on Tissue Engineering and Regenerative Medicine |
| Event Date | 28 September 2026 – 30 September 2026 |
| Event Status | Upcoming |
| Venue | Delta Hotels Heathrow Windsor |
| City | London / Slough corridor |
| State / Region | England |
| Country | United Kingdom |
| Organizer | Organizer not conclusively verified from the supplied materials |
| Official Event Website | Official event website not verified from the supplied materials |
| Event Type | International scientific conference / research and industry networking event |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research |
| Audience Reach | Likely global, with strongest practical reach across the UK, wider Europe, and international academic and biotech networks |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. |
| Attendance Data Reliability | Low for quantitative metrics; only user-supplied event details and reference wording were available for this data sheet |
| Main Purpose of Event | To convene researchers, clinicians, translational medicine leaders, biotech stakeholders, and technology providers around tissue engineering, regenerative medicine, biomaterials, stem cells, and commercialization pathways |
About the Event
The 6th Edition of the International Conference on Tissue Engineering and Regenerative Medicine is positioned as a specialist scientific and translational medicine conference focused on tissue regeneration, stem cell applications, biomaterials, biofabrication, and related therapeutic and clinical-development pathways. Based on the supplied event brief, the conference is intended to bring together academic researchers, clinicians, biotechnology stakeholders, and innovation partners working across regenerative medicine.
From a commercial and lead-generation perspective, the event matters because it can attract decision influencers involved in research partnerships, technology evaluation, clinical translation, laboratory procurement, cell-therapy development, and innovation funding. Even where direct enterprise-scale procurement may be narrower than at a large commercial expo, the conference is still relevant for suppliers targeting research institutions, biotech firms, translational centers, university labs, hospital innovation teams, and strategic collaborators in regenerative medicine.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Academic research leaders | Universities, biomedical engineering departments, stem cell institutes | Influence lab equipment, reagents, imaging, biomaterials, software, and collaboration decisions | High relevance for research tools, instrumentation, CRO partnerships, and sponsored collaborations |
| Clinical and translational medicine teams | Teaching hospitals, NHS trusts, translational centers, clinician-scientist groups | Influence trial design, clinical adoption pathways, therapeutic evaluation, and hospital research sourcing | Relevant for cell therapy platforms, biomaterials, biobanking, diagnostics, and translational partnerships |
| Biotech R&D and platform teams | Cell therapy, regenerative medicine, biomaterials, tissue engineering startups and scale-ups | Direct or shared decision-making on platforms, assays, manufacturing tools, CDMO support, and partnerships | Very relevant for product demos, technical sales, co-development, and licensing conversations |
| Pharma innovation and advanced therapies teams | Large pharmaceutical and specialty therapeutics organizations | Assess pipelines, partnerships, translational assets, and external innovation opportunities | High-value targets for partnering, licensing, and strategic supply relationships |
| Laboratory procurement and operations teams | Research institutes, university labs, biotech companies, hospital R&D centers | Manage sourcing of instruments, consumables, lab services, and workflow systems | Direct buyer relevance for recurring laboratory and facility purchases |
| Technology commercialization and partnerships teams | Universities, innovation centers, biotech firms, catapult organizations | Drive licensing, collaboration, spinouts, and industry partnerships | Useful for solution providers offering commercial scale-up, IP support, and partner access |
| Regulatory and quality stakeholders | Advanced therapy developers, hospital manufacturing units, translational organizations | Influence vendor approval, compliance workflows, and clinical-grade process adoption | Relevant for GMP, QA, validation, traceability, and regulatory consulting vendors |
| Investors and grant/funding ecosystem participants | Translational funds, venture groups, public innovation bodies, research councils | Influence financing, scale-up, and ecosystem partnerships rather than direct purchasing | Relevant for strategic positioning, portfolio partnerships, and market validation |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city corridor | London, Slough, Heathrow, West London research and healthcare network | High | Accessible venue for London universities, NHS institutions, biotech teams, and fly-in delegates via Heathrow |
| Host region | Greater London, South East England, Oxford-Cambridge-London life sciences triangle | Very High | Strong concentration of universities, biotech firms, translational centers, and advanced therapy stakeholders |
| Nearby business and research hubs | Oxford, Cambridge, Stevenage, Reading, Guildford, Birmingham, Manchester, Edinburgh | High | Key origin points for university research, cell and gene therapy, medtech, and pharma R&D |
| National reach | United Kingdom-wide | Medium to High | Conference topic is specialized but nationally relevant to biomedical research, hospitals, and advanced therapies |
| International reach | Europe, North America, Middle East, and Asia-Pacific scientific communities | Medium | The term “International Conference” and Heathrow-adjacent venue suggest overseas participation, but current-year country mix is not publicly confirmed |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The conference branding and subject matter indicate international scientific participation, especially from regenerative medicine and biomedical research communities |
| Regional / National | Secondary practical concentration | For direct outreach and buyer targeting, the strongest concentration is likely the UK and nearby European life sciences ecosystem |
4. Sample Buyer Companies and Websites
Current-year attendee, speaker, sponsor, and exhibitor organization lists were not publicly verified from the supplied materials. The table below is therefore an outreach-planning list of high-fit buyer-side and decision-influencer organizations relevant to regenerative medicine in the UK and Europe. These are not confirmed attendees for the 2026 edition.
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Cell and Gene Therapy Catapult | Innovation / translational organization | Directly aligned with advanced therapies, process development, commercialization, and ecosystem partnerships | ct.catapult.org.uk | Director Translational Development, Head of Manufacturing, Partnerships Director, Procurement Manager | Strong Market Fit, Attendance Not Confirmed |
| NHS Blood and Transplant | Public healthcare / clinical research organization | Relevant for tissue services, translational clinical pathways, and regulated biological materials workflows | nhsbt.nhs.uk | Clinical Director, Head of Tissue Services, Procurement Lead, Quality Manager | Strong Market Fit, Attendance Not Confirmed |
| Guy’s and St Thomas’ NHS Foundation Trust | Teaching hospital / research healthcare buyer | Large academic medical center with translational research and clinician-scientist engagement potential | gstt.nhs.uk | Research Director, Consultant Surgeon, Innovation Lead, Procurement Manager | Strong Market Fit, Attendance Not Confirmed |
| Imperial College London | University / research buyer | Major biomedical engineering and translational science institution in the host market | imperial.ac.uk | Professor, Principal Investigator, Lab Manager, Research Operations Manager | Strong Market Fit, Attendance Not Confirmed |
| King’s College London | University / research buyer | Strong relevance in regenerative medicine, biomaterials, and clinical collaboration networks | kcl.ac.uk | Head of Department, Principal Investigator, Core Facility Manager, Procurement Officer | Strong Market Fit, Attendance Not Confirmed |
| University College London | University / research buyer | Relevant for biomedical engineering, cell biology, and translational research sourcing | ucl.ac.uk | Professor, Research Group Leader, Laboratory Manager, Research Procurement | Strong Market Fit, Attendance Not Confirmed |
| University of Oxford | University / research buyer | Key life sciences institution within the UK translational medicine corridor | ox.ac.uk | Principal Investigator, Translational Research Lead, Lab Operations Manager, Technology Transfer Lead | Strong Market Fit, Attendance Not Confirmed |
| University of Cambridge | University / research buyer | Relevant for stem cell, bioengineering, and commercialization-linked research programs | cam.ac.uk | Professor, Group Leader, Head of Platform, Procurement Business Partner | Strong Market Fit, Attendance Not Confirmed |
| The Francis Crick Institute | Research institute | High relevance for advanced biological research, imaging, cell science, and collaborative innovation | crick.ac.uk | Scientific Operations Director, Core Facility Lead, Group Leader, Procurement Manager | Strong Market Fit, Attendance Not Confirmed |
| RoslinCT | Cell and gene therapy manufacturing organization | Relevant for GMP manufacturing, scale-up, and advanced therapies supply-chain decisions | roslinct.com | Manufacturing Director, QA Director, MSAT Lead, Strategic Sourcing Manager | Strong Market Fit, Attendance Not Confirmed |
| Adaptimmune | Advanced therapies biotech | Relevant buyer for cell-therapy development, process technologies, and translational partnerships | adaptimmune.com | VP Technical Operations, Head of Procurement, CMC Director, Alliance Manager | Strong Market Fit, Attendance Not Confirmed |
| AstraZeneca | Pharmaceutical innovation buyer | Potential partner and buyer for translational science, biologics platforms, and external innovation sourcing | astrazeneca.com | External Innovation Director, Translational Medicine Director, Procurement Director, Alliance Lead | Strong Market Fit, Attendance Not Confirmed |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Principal Investigator / Professor | Research | Director / VP / CXO equivalent in academia | Shapes platform selection, grant-backed purchasing, and collaboration decisions |
| 2 | Director of Translational Medicine | Clinical / R&D | Director | Connects research to clinical application and evaluates enabling technologies |
| 3 | Head of R&D / Scientific Director | Research & Development | Director / VP | High-value buyer/influencer for development platforms, assays, biomaterials, and services |
| 4 | Laboratory Manager / Core Facility Manager | Laboratory Operations | Manager | Often controls day-to-day sourcing and vendor evaluation |
| 5 | Procurement Manager | Procurement | Manager | Key for approved vendor access and framework purchasing |
| 6 | Strategic Sourcing Manager | Supply Chain / Procurement | Manager | Relevant for larger biotech, CDMO, and pharma targets |
| 7 | CMC Director / MSAT Lead | Manufacturing / Technical Operations | Director / Senior Manager | Important for process development, scale-up, and GMP-aligned supplier decisions |
| 8 | Business Development Director | Business Development | Director | Critical for partnerships, licensing, and co-development outreach |
| 9 | Technology Transfer / Partnerships Director | Partnerships / Commercialization | Director | Strong target within universities and translational institutes |
| 10 | Quality Director / Regulatory Affairs Lead | Quality / Regulatory | Director / Manager | Influences approval and deployment of compliant products and services |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Biotechnology | Core fit for regenerative medicine developers, stem cell companies, and platform innovators | Direct technology buyers, R&D partners, and advanced therapy developers |
| 2 | Pharmaceuticals | Large pharma may attend for external innovation, translational science, and therapeutic partnerships | Licensing, co-development, and strategic sourcing |
| 3 | Research | Applies to institutes, translational centers, and specialist labs | Research collaborations, equipment, software, and services |
| 4 | Higher Education | Universities are major stakeholders in tissue engineering and regenerative medicine research | Lab procurement, grants, technology transfer, and academic partnerships |
| 5 | Hospital & Health Care | Clinicians and hospital-based research teams are relevant translational buyers | Clinical validation, research procurement, and hospital innovation projects |
| 6 | Medical Devices | Relevant for scaffolds, implantables, biomaterials, and enabling devices | Product sourcing, development, and clinical partnerships |
| 7 | Information Technology & Services | Relevant where bioinformatics, lab informatics, and digital research infrastructure are involved | LIMS, data workflows, imaging analysis, and research platforms |
| 8 | Government Administration | Public hospitals, health agencies, and research funders may influence funding or procurement ecosystems | Public-sector partnerships and translational funding access |
| 9 | Nanotechnology | Relevant for biomaterials, delivery systems, and scaffold engineering | Materials innovation and platform collaboration |
| 10 | Management Consulting | Supports regulatory, strategy, commercialization, and market-entry work in advanced therapies | Advisory services and strategic partnership development |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Attendance figure not publicly confirmed by the organizer. | Unconfirmed | No verified official metric in supplied materials | Quantitative attendance should be rechecked before using in sales collateral |
| Exhibitor count | Not publicly confirmed | Unconfirmed | No verified exhibitor prospectus or directory provided | Conference format may feature a limited tabletop or sponsor presence rather than a large expo floor |
| Buyer count | Not publicly confirmed | Unconfirmed | No official buyer program identified | This event is more likely to attract research and clinical decision influencers than formal hosted buyers |
| Speaker count | Not publicly confirmed | Unconfirmed | No verified agenda or speaker roster provided | Likely multi-session scientific agenda based on supplied description |
| Sponsor count | Not publicly confirmed | Unconfirmed | No verified sponsor list provided | Sponsor mix should be reviewed once event media kit is available |
| Historical attendance | Historical attendance not verified | Historical / prior-year evidence unavailable | No prior-year official metrics supplied | Prior-year official brochures or recap pages would improve targeting confidence |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Tissue engineering | Scaffolds, biomaterials, models, culture systems | Technical demos, pilot studies, co-development | Biomaterials, scaffold technologies, culture platforms |
| Stem cell therapies | Cell expansion, characterization, QC, translational workflows | Scientific validation, partnership discussions, sourcing meetings | Cell processing systems, analytics, GMP support, media and reagents |
| 3D biofabrication | Bioinks, bioprinters, workflow software, imaging | Platform evaluation and lab adoption discussions | Bioprinting platforms, design software, imaging and validation tools |
| Biomaterials and implants | Novel materials, safety evidence, translational compatibility | Clinical and R&D buyer education | Materials science solutions, testing services, regulatory support |
| Clinical translation | Path from discovery to patient-ready application | Hospital collaborations and translational service positioning | Clinical trial support, translational consulting, compliant manufacturing |
| Commercialization and partnerships | Licensing, alliances, scale-up, investor readiness | Business development meetings and ecosystem networking | CDMO services, consulting, licensing support, partnership programs |
| Regulatory and ethics | Compliance, documentation, governance, clinical readiness | High-value conversations with quality and regulatory leaders | Regulatory advisory, QA systems, traceability and validation tools |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | High | Strong relevance for scientific, clinical, translational, and specialized life sciences suppliers |
| Decision-maker availability | Medium to High | Scientific leaders and partnership contacts are likely present; formal procurement contacts may be fewer than at a procurement-focused expo |
| Data collection potential | Medium | Good for high-value named prospects if agenda and speaker lists are published; weaker if only generic registration is available |
| Apollo targeting potential | High | The audience maps well to Biotechnology, Pharmaceuticals, Research, Higher Education, and Hospital & Health Care filters |
| Geographic targeting potential | High | London and the UK life sciences triangle provide a focused territory for pre-event and post-event outreach |
| Best outreach approach | High | Use scientific relevance, partnership language, translational outcomes, and technical use cases rather than generic sales messaging |
| Overall lead quality | High | Best suited to niche, high-value outreach rather than mass-volume attendee list sales |
| Best use case | High | ABM targeting, speaker-based prospecting, university and biotech outreach, partnership development, and lab technology sales |
| Limitations / risks | Medium | Current-year participant data has not been verified; supplied materials include a date/location inconsistency that must be resolved before campaign launch |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Biotechnology; Pharmaceuticals; Research; Higher Education; Hospital & Health Care; Medical Devices; Government Administration; Information Technology & Services | Build the highest-fit universe around regenerative medicine and translational science |
| Departments | Research; Engineering; Operations; Procurement; Business Development; Quality Assurance; Regulatory Affairs; Medical / Clinical | Capture both technical evaluators and commercial decision-makers |
| Seniority | CXO; VP; Director; Head; Manager; Partner; Professor / Principal Investigator equivalent where mappable | Focus on approval authority and strong technical influence |
| Job titles | Principal Investigator, Professor, Scientific Director, Director Translational Medicine, Head of R&D, Laboratory Manager, Core Facility Manager, Procurement Manager, Strategic Sourcing Manager, CMC Director, MSAT Lead, Business Development Director, Alliance Manager, Regulatory Affairs Director, Quality Director | Prioritize scientific buyers, innovation leaders, and procurement-involved contacts |
| Geography | United Kingdom first; then Ireland, Germany, Netherlands, Switzerland, France, Sweden, Denmark, Belgium, United States | Reflects likely event catchment and strong regenerative medicine clusters |
| Employee size | 11-50; 51-200; 201-500; 501-1000; 1001-5000; 5001+ | Include both venture-backed biotechs and large research/pharma institutions |
| Keywords | tissue engineering, regenerative medicine, stem cell, cell therapy, biofabrication, biomaterials, scaffold, organoid, translational medicine, advanced therapies, GMP, cell processing | Improve relevance within broad life sciences categories |
| Technologies | Use only if relevant to client: LIMS, bioprinting, imaging, GMP manufacturing, cryostorage, cell analysis, bioreactors | Narrow to solution-specific accounts |
| Revenue range | Optional: mid-market to enterprise for pharma and CDMO; no strict filter for universities or institutes | Avoid excluding high-fit research institutions with non-standard revenue profiles |
| Company type | Public companies, private companies, nonprofit / academic organizations, government-linked healthcare bodies | Covers the full buyer ecosystem relevant to this event |
Suggested Apollo Search Logic: ("tissue engineering" OR "regenerative medicine" OR "stem cell" OR "cell therapy" OR biomaterials OR biofabrication OR organoid OR scaffold) AND (Director OR Head OR Manager OR VP OR Professor OR "Principal Investigator") AND (R&D OR Research OR Procurement OR Operations OR Clinical OR Partnerships). Start with United Kingdom geography, then expand to Western Europe and selected North American clusters.
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| User-provided event details | Provided briefing data | Event title, London-area venue, United Kingdom location, start date 2026-09-28, end date 2026-09-30 | Medium |
| User-provided reference description | Reference wording | Topic scope, likely audience profile, scientific focus areas, conference purpose | Medium |
| Delta Hotels Heathrow Windsor | Venue website | Venue identity and Heathrow/Windsor location context | High |
| Cell and Gene Therapy Catapult | Organization website | Buyer-side market relevance within UK advanced therapies ecosystem | High |
| NHS Blood and Transplant | Organization website | Public healthcare and tissue-services relevance for regenerative medicine sourcing and clinical translation | High |
| Imperial College London; King’s College London; UCL; University of Oxford; University of Cambridge | Organization websites | High-fit academic and research buyer ecosystem around the host market | High |
Verification note: The supplied reference description contains conflicting event timing and location language, mentioning Berlin, Germany and 18–20 November 2026, while the user-supplied event details specify London, United Kingdom and 28–30 September 2026. For campaign accuracy, the organizer name, official website, final venue city labeling, and current-year agenda should be re-verified before using this event for attendee list building, attendance forecasting, or confirmed-participant claims.
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 6th Edition of International Conference on Tissue Engineering and Regenerative Medicine — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds